NICE publishes febuxostat guidance after appeal fails
This article was originally published in Scrip
The UK's National Institute for health and Clinical Excellencehas published guidance on the use ofIpsen's Adenuric (febuxostat, licensed from Teijin Pharma) for the treatment of chronic hyperuricaemia in gout after dismissing the company's appeal against a draft appraisal (Scrip Online, August 19th, 2008).
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.